| RV disease burden (95% CI)a |   RV disease costsa(€ million) | Vaccination costs (€ million) | ||||
---|---|---|---|---|---|---|---|
 | Disease episodes (x1000) | Hospitalizationsb | Fatal cases | QALY’s lost (undiscounted) | Direct healthcare costs (undiscounted) | Societal costs (undiscounted) | (undiscounted) |
No vaccination | 74.1(57.8; 90.0) | 4,870 (4,310; 5,430) | 6.5 (3.2; 11.0) | 257 (136; 422) | 11.9 (10.5; 13.3) | 18.2 (16.2; 20.3) | - |
Targeted RV vaccination | Â | Â | Â | Â | Â | Â | Â |
RV1 | 67.3 (51.3; 82.4) | 4,370 (3,890; 4,870) | 0.7(0.2; 1.6) | 119 (79; 177) | 10.5 (9.3; 11.8) | 16.4 (14.6; 18.2) | 1.5 |
 Percent reduction | 8% | 10% | 89% | 54% | 12% | 10% |  |
RV5 | 67.4 (51.5; 82.7) | 4,384 (3,892; 4,870) | 0.8 (0.3; 1.7) | 121 (80; 184) | 10.6 (9.4; 11.8) | 16.4 (14.6; 18.2) | 1.6 |
 Percent reduction | 8% | 10% | 88% | 53% | 11% | 10% |  |
Universal RV vaccination | Â | Â | Â | Â | Â | Â | Â |
RV1 | 40.6 (30.1; 51.2) | 1,370 (1,150; 1,650) | 0.4 (0.2; 0.8) | 60 (42; 81) | 3.4 (2 8; 4 1) | 5.9 (5.0; 6.9) | 15.2 |
 Percent reduction | 45% | 72% | 94% | 77% | 71% | 67% |  |
RV5 | 42.6 (31.7; 53.6) | 1,440 (1,210; 1,710) | 0.5(0.2; 0.9) | 66 (45; 91) | 3.6 (3.1; 4.3) | 6.3 (5.3; 7.3) | 16.7 |
 Percent reduction | 43% | 70% | 92% | 75% | 70% | 65% |  |